Status
Please wait ...
EndoNet
The information resource about the endocrine network in human.
Search
Search a component
Browse
Browse pathways
Browse hormones
Browse hormones functions
Browse hormone classification
Browse receptors
Network
Load network
Path analysis
Process network
Help
Help
Statistic
About
Details for phenotype: osteoporosis
Top
General information
Triggers
Toolbox
Click to access the toolbox
Top
General information
Triggers
Toolbox
Click to access the toolbox
EndoNet ID: ENP00500
Add to network
Name
osteoporosis
General information
This phenotype is pathologic
Osteoporosis is characterized by the loss of bone mass and strength that leads to fragility fractures.
[1]
Links to other resources
GO
regulation of bone remodeling
OMIM
166710
Medline Plus
000360
MeSH term
D010024
Disease database
9385
Phenotype triggers
calcitonin receptor
ui-button
in
osteoclast
ui-button
The discovery that calcitonin is a selective inhibitor of osteoclastic activity more than 40 years ago led to the concept that calcitonin deficiency might be the cause of osteoporosis and that its administration might be the cure.
[1]
more activity (high ligand concentration, overexpression) of
glucocorticoid receptor
ui-button
in
macrophage
ui-button
Glucocorticoids suppress osteoblast activity in vivo.
[2]
Glucocorticoid signalling via GR inhibits proliferation of osteoclastogenic cells, apoptosis of mature osteoclasts and osteoclast function in vitro and in vivo, by altering the activity rather than the number of osteoclasts. Glucocorticoid-induced bone mass reduction is not only mediated by directly inhibiting osteoblasts, but also by inhibiting osteoclast activity, which in turn disrupts the remodelling cycle and suppresses osteoblast activity .
[3]
VDR
ui-button
in
bone
ui-button
The primary form of circulating vitamin D, 25-hydroxy-vitamin D, is a modifiable quantitative trait associated with multiple medical outcomes, including osteoporosis.
[4]
Reference